SCHEMBL18105166

SCHEMBL18105166

O=C(N[C@@H](CO)c1nc(-c2cc3cc(F)ccc3[nH]2)no1)c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
ROCK2 O75116 3/20 0.39
ROCK1 Q13464 2/20 0.39
GPER1 Q99527 1/20 0.38
METAP2 P50579 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
CNR2 P34972 1/20 0.36
PYGL P06737 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
SYK P43405 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19835929 1.00 LMNA (0.40) LMNATSHRROCK2ROCK1GPER1
SCHEMBL18105164 0.91 LMNA (0.44) LMNATSHRROCK2ROCK1
SCHEMBL19835720 0.91 LMNA (0.44) LMNATSHRROCK2ROCK1
SCHEMBL18104972 0.84 LMNA (0.40) LMNATSHRROCK2ROCK1HDAC4
SCHEMBL19949367 0.84 LMNA (0.40) LMNATSHRROCK2ROCK1HDAC4
SCHEMBL19835927 0.82 CNR2 (0.36) METAP2CNR2SYK
SCHEMBL18104940 0.82 LMNA (0.47) LMNATSHRROCK2ROCK1HDAC4
SCHEMBL19949370 0.82 LMNA (0.47) LMNATSHRROCK2ROCK1HDAC4
SCHEMBL24386199 0.82 LMNA (0.39) LMNATSHRROCK2ROCK1HDAC4
SCHEMBL18104994 0.82 LMNA (0.39) LMNATSHRROCK2ROCK1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3275440-B1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NAT CT GERIATRICS & GERONTOLOGY (JP) 2022-05-04 EP claimed
EP-3275440-B1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NAT CT GERIATRICS & GERONTOLOGY (JP) 2022-05-04 EP disclosed
EP-3275440-B1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NAT CT GERIATRICS & GERONTOLOGY (JP) 2022-05-04 EP disclosed
US-20180072708-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2018-03-15 US disclosed
US-20180072708-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2018-03-15 US disclosed
EP-3275440-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME National Center for Geriatrics and Gerontology (JP) 2018-01-31 EP disclosed
EP-3275440-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME National Center for Geriatrics and Gerontology (JP) 2018-01-31 EP disclosed
WO-2016153023-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME 国立研究開発法人国立長寿医療研究センター 2016-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072708-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME APP, BACE1, PSEN1 LMNA 1473/4885TSHR 3747/4885ROCK2 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.